3.76
price up icon11.24%   0.38
after-market Handel nachbörslich: 3.78 0.02 +0.53%
loading

Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten

pulisher
03:10 AM

What analysts say about Larimar Therapeutics Inc. stockHigh-velocity capital appreciation - Autocar Professional

03:10 AM
pulisher
08:25 AM

What drives Larimar Therapeutics Inc. stock priceRapidly expanding wealth - jammulinksnews.com

08:25 AM
pulisher
Jul 22, 2025

Is Larimar Therapeutics Inc. a good long term investmentMarket-leading capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

Jul 21, 2025
pulisher
Jul 19, 2025

Larimar Therapeutics Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Return Investment Tips - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why Larimar Therapeutics Inc. stock attracts strong analyst attentionTop Analyst Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN

Jul 12, 2025
pulisher
Jul 09, 2025

Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews

Jul 09, 2025
pulisher
Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan

Jul 08, 2025
pulisher
Jun 30, 2025

Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN

Jun 25, 2025
pulisher
Jun 25, 2025

Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World

Jun 25, 2025
pulisher
Jun 24, 2025

Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

Larimar Therapeutics (LRMR) Target Price Reduced by Wedbush Amid FDA Delay | LRMR Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 23, 2025

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program | LRMR Stock News - GuruFocus

Jun 23, 2025
pulisher
Jun 21, 2025

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times

Jun 21, 2025
pulisher
Jun 20, 2025

Larimar Therapeutics Announces Regulatory Update Call on - GlobeNewswire

Jun 20, 2025
pulisher
Jun 17, 2025

Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 04, 2025
pulisher
May 28, 2025

Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

May 28, 2025
pulisher
May 23, 2025

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN

May 23, 2025
pulisher
May 23, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa

May 23, 2025
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):